These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 30730771

  • 1. Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases.
    Pérez-Lloret S, Quarracino C, Otero-Losada M, Rascol O.
    Expert Opin Pharmacother; 2019 Apr; 20(6):635-645. PubMed ID: 30730771
    [Abstract] [Full Text] [Related]

  • 2. Droxidopa in neurogenic orthostatic hypotension.
    Kaufmann H, Norcliffe-Kaufmann L, Palma JA.
    Expert Rev Cardiovasc Ther; 2015 Apr; 13(8):875-91. PubMed ID: 26092297
    [Abstract] [Full Text] [Related]

  • 3. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B).
    Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G.
    Mov Disord; 2015 Apr 15; 30(5):646-54. PubMed ID: 25487613
    [Abstract] [Full Text] [Related]

  • 4. L-threo-dihydroxyphenylserine (L-threo-DOPS; droxidopa) in the management of neurogenic orthostatic hypotension: a multi-national, multi-center, dose-ranging study in multiple system atrophy and pure autonomic failure.
    Mathias CJ, Senard JM, Braune S, Watson L, Aragishi A, Keeling JE, Taylor MD.
    Clin Auton Res; 2001 Aug 15; 11(4):235-42. PubMed ID: 11710796
    [Abstract] [Full Text] [Related]

  • 5. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial.
    Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, Mauney J, Feirtag M, Mathias CJ, NOH301 Investigators.
    Neurology; 2014 Jul 22; 83(4):328-35. PubMed ID: 24944260
    [Abstract] [Full Text] [Related]

  • 6. Droxidopa in patients with neurogenic orthostatic hypotension associated with Parkinson's disease (NOH306A).
    Hauser RA, Hewitt LA, Isaacson S.
    J Parkinsons Dis; 2014 Jul 22; 4(1):57-65. PubMed ID: 24326693
    [Abstract] [Full Text] [Related]

  • 7. Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension.
    Elgebaly A, Abdelazeim B, Mattar O, Gadelkarim M, Salah R, Negida A.
    Clin Auton Res; 2016 Jun 22; 26(3):171-80. PubMed ID: 26951135
    [Abstract] [Full Text] [Related]

  • 8. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa.
    Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H, Droxidopa 302 Investigators.
    Hypertension; 2015 Jan 22; 65(1):101-7. PubMed ID: 25350981
    [Abstract] [Full Text] [Related]

  • 9. Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa.
    Isaacson SH, Skettini J.
    Vasc Health Risk Manag; 2014 Jan 22; 10():169-76. PubMed ID: 24729712
    [Abstract] [Full Text] [Related]

  • 10. Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension.
    Keating GM.
    Drugs; 2015 Feb 22; 75(2):197-206. PubMed ID: 25559422
    [Abstract] [Full Text] [Related]

  • 11. Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303).
    Isaacson S, Shill HA, Vernino S, Ziemann A, Rowse GJ.
    J Parkinsons Dis; 2016 Oct 19; 6(4):751-759. PubMed ID: 27636856
    [Abstract] [Full Text] [Related]

  • 12. Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension.
    Biaggioni I, Arthur Hewitt L, Rowse GJ, Kaufmann H.
    BMC Neurol; 2017 May 12; 17(1):90. PubMed ID: 28494751
    [Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness of droxidopa in patients with neurogenic orthostatic hypotension: post-hoc economic analysis of Phase 3 clinical trial data.
    François C, Hauser RA, Aballéa S, Dorey J, Kharitonova E, Hewitt LA.
    J Med Econ; 2016 May 12; 19(5):515-25. PubMed ID: 26710315
    [Abstract] [Full Text] [Related]

  • 14. L-dihydroxyphenylserine (Droxidopa) in the treatment of orthostatic hypotension: the European experience.
    Mathias CJ.
    Clin Auton Res; 2008 Mar 12; 18 Suppl 1():25-9. PubMed ID: 18368304
    [Abstract] [Full Text] [Related]

  • 15. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension.
    Palma JA, Norcliffe-Kaufmann L, Martinez J, Kaufmann H.
    Neurology; 2018 Oct 16; 91(16):e1539-e1544. PubMed ID: 30232253
    [Abstract] [Full Text] [Related]

  • 16. Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease.
    Hauser RA, Biaggioni I, Hewitt LA, Vernino S.
    Mov Disord Clin Pract; 2018 Oct 16; 5(6):627-634. PubMed ID: 30637284
    [Abstract] [Full Text] [Related]

  • 17. Norepinephrine precursor therapy in neurogenic orthostatic hypotension.
    Kaufmann H, Saadia D, Voustianiouk A, Goldstein DS, Holmes C, Yahr MD, Nardin R, Freeman R.
    Circulation; 2003 Aug 12; 108(6):724-8. PubMed ID: 12885750
    [Abstract] [Full Text] [Related]

  • 18. Diagnosing and treating neurogenic orthostatic hypotension in primary care.
    Kuritzky L, Espay AJ, Gelblum J, Payne R, Dietrich E.
    Postgrad Med; 2015 Aug 12; 127(7):702-15. PubMed ID: 26012731
    [Abstract] [Full Text] [Related]

  • 19. L-dihydroxyphenylserine (Droxidopa): a new therapy for neurogenic orthostatic hypotension: the US experience.
    Kaufmann H.
    Clin Auton Res; 2008 Mar 12; 18 Suppl 1():19-24. PubMed ID: 18368303
    [Abstract] [Full Text] [Related]

  • 20. Neurogenic orthostatic hypotension: roles of norepinephrine deficiency in its causes, its treatment, and future research directions.
    Loavenbruck A, Sandroni P.
    Curr Med Res Opin; 2015 Nov 12; 31(11):2095-104. PubMed ID: 26373628
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.